{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:09:51Z","timestamp":1759057791061},"reference-count":34,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.antiviral.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T12:36:16Z","timestamp":1360758976000},"page":"19-26","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system"],"prefix":"10.1016","volume":"98","author":[{"given":"Jason","family":"Lamontagne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cally","family":"Goddard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Cuconati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanyong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.02.001_b0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.antiviral.2010.02.325","article-title":"Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro","volume":"86","author":"Bader","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.02.001_b0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/tx00046a004","article-title":"Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen","volume":"8","author":"Breinholt","year":"1995","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0015","doi-asserted-by":"crossref","first-page":"14601","DOI":"10.1073\/pnas.251536898","article-title":"Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer","volume":"98","author":"Egner","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.02.001_b0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1073\/pnas.0912966107","article-title":"Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection","volume":"107","author":"Gastaminza","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.02.001_b0025","first-page":"204","article-title":"Total synthesis of chlorophyll and its biosynthesis","volume":"55","author":"Godnev","year":"1963","journal-title":"Usp. Sovrem. Biol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0030","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0035","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1128\/JVI.00541-07","article-title":"Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway","volume":"81","author":"Guo","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0040","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/AAC.00989-10","article-title":"Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses","volume":"55","author":"Guo","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.02.001_b0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cld.2010.05.005","article-title":"Antiviral therapy for chronic hepatitis B","volume":"14","author":"Jafri","year":"2010","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2013.02.001_b0050","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/gut.33.8.1094","article-title":"Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B","volume":"33","author":"Janssen","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2013.02.001_b0055","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/BF02877700","article-title":"Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B","volume":"24","author":"Kartal","year":"2007","journal-title":"Adv. Ther."},{"key":"10.1016\/j.antiviral.2013.02.001_b0060","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1128\/JVI.77.19.10288-10294.2003","article-title":"New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products","volume":"77","author":"Kocisko","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0065","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.02.001_b0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/JVI.01249-09","article-title":"Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis","volume":"84","author":"Lamontagne","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2893.1994.tb00110.x","article-title":"Treatment of chronic hepatitis B","volume":"1","author":"Lok","year":"1994","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2013.02.001_b0080","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1128\/JVI.70.4.2277-2285.1996","article-title":"Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line","volume":"70","author":"Lu","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/222574b0","article-title":"Electron microscope study of the viricidal properties of sodium magnesium-chlorophyllin","volume":"222","author":"Mekler","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2013.02.001_b0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ab.2008.01.017","article-title":"A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization","volume":"375","author":"Muller","year":"2008","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.antiviral.2013.02.001_b0095","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O\u2019Connor","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2013.02.001_b0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2010.04.075","article-title":"Novel fluorescent cycloheximide derivatives for the imaging of protein synthesis","volume":"396","author":"Paoletti","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2013.02.001_b0105","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1073\/pnas.0511066103","article-title":"A role for chlorophyllide a oxygenase in the regulated import and stabilization of light-harvesting chlorophyll a\/b proteins","volume":"103","author":"Reinbothe","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2013.02.001_b0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0002-9394(99)00114-2","article-title":"The survival of herpes simplex virus in multidose office ophthalmic solutions","volume":"128","author":"Romanowski","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0165-1110(94)90017-5","article-title":"Chlorophyll and chlorophyllin as modifiers of genotoxic effects","volume":"318","author":"Sarkar","year":"1994","journal-title":"Mutat. Res. \u2013 Rev. Genetic Toxicol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0120","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1128\/JVI.62.8.2836-2844.1988","article-title":"Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions","volume":"62","author":"Sells","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/187152609787847677","article-title":"Drug targets in hepatitis B virus infection","volume":"9","author":"Stein","year":"2009","journal-title":"Infect. Disord. Drug Targets"},{"key":"10.1016\/j.antiviral.2013.02.001_b0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1463-5224.2002.00234.x","article-title":"Survival of equine herpesvirus-4, feline herpesvirus-1, and feline calicivirus in multidose ophthalmic solutions","volume":"5","author":"Storey","year":"2002","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0135","first-page":"119","article-title":"Old drugs resurrected?","volume":"10","author":"Thomas","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2013.02.001_b0140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1747-0285.2006.00391.x","article-title":"Searching for new antimalarial therapeutics amongst known drugs","volume":"67","author":"Weisman","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.antiviral.2013.02.001_b0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.56.062404.172936","article-title":"Approaches to therapy of prion diseases","volume":"56","author":"Weissmann","year":"2005","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.antiviral.2013.02.001_b0150","first-page":"172","article-title":"Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment","volume":"11","author":"Wu","year":"2012","journal-title":"HBPD Int."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2013.02.001_b0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: Evolution over two decades","volume":"26","author":"Yuen","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2013.02.001_b0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.antiviral.2013.02.001_b0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095632020901900404","article-title":"Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside\/nucleotide analogues","volume":"19","author":"Zhu","year":"2009","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2013.02.001_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(04)00162-7","article-title":"Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection","volume":"64","author":"Zoulim","year":"2004","journal-title":"Antiviral Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T07:59:18Z","timestamp":1595404758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0166354213000247"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.02.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}